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of great interest in high-grade serous ovarian cancer. How-
ever, both spatial and temporal intratumoral genetic hetero-
geneity is a major challenge for personalized medicine, and 
greater knowledge of the molecular rules that drive tumor 
evolution through space and time is required to achieve a 
long-term clinical benefit from personalized therapy.
Keywords Ovarian cancer · Clonal evolution · Drug 
resistance · Genetic heterogeneity · Genomic instability
Introduction
High-grade serous ovarian cancer (HGSOC), the most 
common and aggressive form of the epithelial ovarian 
cancer (EOC), remains the leading cause of cancer-related 
death among all gynecological cancers in the developed 
parts of the world [1, 2].
The majority of cases show a significant, but transient 
response to standard therapy including debulking surgery 
followed by platinum-based chemotherapy, and the devel-
opment of resistance is almost permanently inscribed in 
the clinical course of the disease [3]. Therefore, the emer-
gence of drug-resistant disease is a major problem in the 
clinical management of HGSOC, and in the context of the 
still unsatisfactory treatment outcomes, deciphering the 
molecular mechanisms that contribute to drug resistance 
is the greatest challenge in the area of HGSOC molecular 
research.
The last 5 years’ studies using next-generation sequenc-
ing provided evidences that many types of solid tumors 
present spatial and temporal genetic heterogeneity and 
are composed of multiple populations of genetically dis-
tinct subclones that evolve over time following a pattern of 
branched evolution in a similar manner to the Darwinian 
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evolution of species [4–9]. This evolutionary nature of 
cancer has been proposed as the major contributor to drug 
resistance and treatment failure [10].
In this review, we present the current state of knowledge 
about the clonal evolution (CE) of HGSOC and discuss the 
challenge that CE poses for efforts to achieve an optimal 
cancer control.
Genomic instability in HGSOC
Large-scale genomic analyses demonstrated that HGSOC 
exhibits a high degree of genomic instability (GI) arising 
as a result of DNA repair defects caused mainly by TP53 
mutations and homologous recombination (HR) deficiency, 
occurring in 96% and almost 50% of cases, respectively 
[11, 12]. During tumorigenesis GI promotes the acquisi-
tion of further DNA alterations leading to genetic diver-
sity between cancer cells and creating the possibility of 
coexistence of genetically distinct subclones within the 
same tumor [13]. Therefore, GI is a source of intratumoral 
genetic heterogeneity (ITH) and one of the most impor-
tant driving forces of CE. Subclones can benefit from GI 
by acquiring new genomic events that confer a selective 
advantage during ongoing evolution, thus a high level of GI 
is generally associated with emerging of treatment resist-
ance and poor prognosis in various cancer types [14–16]. 
However, a high degree of GI can also have an unfavora-
ble effect on the fitness of cancer subclones by enabling 
the acquisition of deleterious genomic alterations that pro-
vide a selective disadvantage [17] and, consequently, limit 
tumor growth, and/or increase tumor response to the cyto-
toxic therapy. This is particularly true for HGSOC, where 
the studies have shown that a greater level of GI is asso-
ciated with improved outcomes, mainly due to a higher 
response rate to platinum-based chemotherapy [18, 19]. It 
is consistent with clinical observations that HR-deficient 
cases with a highly unstable genome exhibit enhanced 
platinum sensitivity and improved overall survival (OS) 
compared to HR-intact cases [20]. Since HR deficiency 
is associated with better response to platinum agents, the 
restoration of BRCA1 and BRCA2 function is thought to 
play an important role in emerging of platinum resistance 
[21]. Recently, the large-scale genomic analysis of chem-
oresistant HGSOC, showed HR deficiency only in 2 out 
of 12 platinum-refractory cases (both as a consequence of 
the somatic methylation of BRCA1 which cannot be con-
sidered as an equivalent to germline mutation) while rever-
sions of germline BRCA1/2 mutations have been found 
in 5 out of 10 relapse cases. Moreover, one autopsy case 
was found to have several independent subclonal BRCA2 
reversion events detected in the different tumor metastatic 
sites at the time of relapse [12]. Therefore, it appears that in 
some HGSOC cases an optimal level of GI may be required 
to provide cancer subclones with the ability to survive and 
to expand under selective pressure of chemotherapy. Fur-
ther instability, may in turn be unfavorable for subclones 
leading to their increased chemosensitivity. This hypothesis 
is supported by a recent report demonstrating an increase 
in genomic stability within the residual subclones after the 
course of neoadjuvant chemotherapy [22]. Further studies 
should evaluate how various levels of GI, which are seen in 
HGSOC, affect the ITH, the tumor evolutionary potential 
and, ultimately, the tumor response to the treatment.
Clonal evolution of pre-treatment disease
To investigate clonal heterogeneity in HGSOC, Bashashati 
et  al. obtained 29 spatially separated samples from 5 
patients with newly diagnosed stage III–IV HGSOC [7]. 
Exome sequencing, copy number analysis, target amplicon 
deep sequencing and gene expression profiling confirmed 
the presence of extensive intratumoral genomic and tran-
scriptomic heterogeneity with TP53 mutation as the clon-
ally dominant key driver event acquired early in the tumo-
rigenesis. Importantly, alterations in key driver genes such 
as PIK3CA, CTNNB1, PDGFR, NF1, SH3GL1, RBM15 
were found to be subclonal, indicating that they have been 
acquired during tumor evolution and confirming that key 
driver events contributing to cancer initiation, progression 
and maintaince are not always clonally dominant (present 
in all cancer cells), but also can be present subclonally (pre-
sent only in a subset of cancer cells) [4, 5, 23]. These sub-
clonal mutations along with non-genetic factors can lead 
to a phenotypic diversity between cancer cells and provide 
the fitness advantage to subclones, reducing clinical benefit 
of cancer therapy [23, 24]. Indeed, some of the subclonal 
mutations found by Bashashati et al. were associated with 
alteration in gene expression profile supporting their role in 
shaping subclonal phenotypes and intratumoral phenotypic 
heterogeneity.
The results reported by Hoogstrat et al. [25] highlighted 
that the patterns of CE vary across HGSOC cases. These 
findings also suggest that CE may occur independently at 
the level of mutational processes as well as genomic rear-
rangements, and alterations in genomic rearragements may, 
independently from mutations, affect the intratumoral phe-
notypic diversity. They took 15 spatially separated samples 
from different tumor sites from 2 treatment-naive patients 
with stage IIIC–IV HGSOC. The first case showed exten-
sive genomic and transcriptomic intratumoral heterogene-
ity with most marked differences in the genomic rearrange-
ment, the gene expression profile and key cancer pathways 
activation between the samples from the primary tumor 
site in the ovary and those obtained from peritoneal and 
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omental metastases. However, the second case was found 
to be much more homogenous with respect to genomic 
rearrangement, mutational profile and gene expression pat-
tern. Importantly, in the first case there were no mutations 
unique to metastatic samples and all mutations identified 
in these samples were also found in samples from the right 
ovary. In the second case only two mutations were unique 
to the tumor metastatic site, whereas all other detected 
mutations were shared between all samples. This supports 
the results from the Lee et al. [26] case report and suggests 
that in some cases of pre-treatment HGSOC, intraperito-
neal metastases may arise with only a little accumulation of 
new somatic mutations.
Studies showed a rather consistent picture of HGSOC 
as a dynamic entity composed of multiple populations of 
genetically and phenotypically distinct subclones evolv-
ing from a single ancestral clone following patient-specific 
patterns of branched evolution [7, 25–27]. In the context 
of complex tumor structure it is most likely that the CE of 
untreated HGSOC is mainly driven by selective pressures 
imposed by highly heterogeneous (both spatially and tem-
porally) tumor microenvironment (TME) [28, 29]. Dur-
ing ongoing evolution, subclones are selected according 
to their fitness to survive in divergent microenvironmental 
conditions [29, 30]. Selection is based on the phenotypes 
and subclones that have phenotypic advantage in given 
environmental landscape undergo further clonal expansion 
[31]. Phenotypes are not, however, the permanent features 
of cancer cells and do not result solely from cell-autono-
mously acting factors [10, 32, 33]. Beyond genetic, epige-
netic, transcriptomic and proteomic factors, also variations 
in local microenvironmental niches may affect phenotypes 
of cancer cells and consequently influence their fitness [10, 
24, 29, 34]. These interactions are not, however, directed 
unilaterally and cancer cells can likewise modulate their 
microenvironments enforcing, e.g., dynamic changes in 
their own phenotypes [24, 35]. Therefore, the TME should 
be considered not simply as a “passive" source of various 
selection forces that promote certain phenotypes, but rather 
as a dynamic, complex structure actively affecting the path-
ways of cancer cell evolution.
It appears that in an advanced-stage HGSOC the pres-
ence of extensive phenotypic diversity as well as noticable 
differences in chemosensivity between cancer cells isolated 
from different tumor deposits [36] can be in part explained 
by divergent selective pressures acting on tumor cell sub-
populations in various metastatic niches. As clinical obser-
vations indicate that in advanced-stage EOC the initial 
disease distribution is prognostically relevant regardless of 
achieving a cytoreduction to microscopic residual disease 
(RD) [37], the role of microenvironmental conditions in 
given metastatic regions in selection or “storage” of resist-
ant subclones leading to tumor maintaince and progression 
should be evaluated in further studies. There is also a need 
to assess whether the metastatic niches in the given meta-
static organ are able to promote repeatable genotypes and 
phenotypes across different HGSOC cases.
The coexistence of genetically dissimilar subclones 
widespread within the three-dimensional (3D) tumor space 
can lead to interclonal interactions which are not limited, 
however, to a simple competition for space and resources 
during ongoing selection [32, 38–40]. As a recent study 
using mouse xenograft model of breast cancer suggests, the 
heterogeneous cancer cell population may include minor 
subclones too indolent to win a competition and grow out/
expand, but able to promote proliferation of other sub-
clones [32]. Along with the results of the study in glio-
blastoma [38], it supports the potentially relevant role of 
minor subclonal populations in driving cancer growth and 
maintaining tumor heterogeneity. Moreover, a study based 
on transgenic mouse model of multiple myeloma suggests 
that the inability of minor subclones to compete efficiently 
does not necessarily lead to their exclusion from the can-
cer cell population by more agressive subclones. Dominant 
subclones may indeed supress minor subclones, but they 
also may coexist with them or even promote their prolif-
eration [40]. These findings shed new light on the role of 
interclonal interactions in cancer evolution and provide 
additional evidence to perceive tumor as a complex topo-
logical “ecosystem” rather than a simple mass of trans-
formed epithelial cells. Recently, several studies revealed 
that 3D models of EOC cell lines that reconstitute complex 
tumor architecture better reflect cancer cells behavior and 
their potential for emergence of resistance than two-dimen-
sional models [41–43] supporting the impact both cell–cell 
and cell–stroma interactions on EOC biology. Due to the 
subclonal complexity of HGSOC, further studies should 
evaluate whether interclonal interactions have a relevant 
effect on tumor evolution prior to the treatment, on tumor 
response to the treatment, as well as on the development 
of platinum-resistant and, especially, platinum-sensitive 
recurrence [44].
HGSOC evolution during the course of treatment
The emergence of treatment resistance followed by initial 
response to standard therapy resulting in tumor relapse 
remains a main clinical problem in the management of 
most HGSOC cases reducing the possibility to cure the 
advanced-stage disease [3, 45].
For heterogeneous tumor cell population, cancer therapy 
constitutes a selection pressure widely affecting the pat-
terns of tumor evolution [10]. Beyond mechanical and/
or cytotoxic eradication of sensitive subclones, treatment-
related selection forces can also favor the expansion of 
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subclones genetically and/or phenotypically best adapted 
to therapy-induced conditions leading to dynamic changes 
in the subclonal composition of cancer [46–48]. It should 
be noted, however, that because of the existence of a struc-
tural complexity of the tumor, the adaptive changes in the 
tumor subclonal architecture that occur during the course 
of treatment probably are not determined solely by the 
direct effect of cancer therapy on cancer cell vitality, but 
also by its impact on TME [49], and by its interference into 
the clonal competition or, in a broader sense, into the inter-
clonal interactions [48].
HGSOC evolution over the course of treatment have 
been analyzed in several studies. Recently, paired tumor 
samples taken before and after first line of platinum-based 
chemotherapy have been compared using whole-exome 
sequencing (WES) and single nucleotide polymorphism 
profiling [50]. While only 58% of somatic mutations were 
conserved between matched tumor biopsies, 27 and 15% 
of them were found to be relapse- and primary-unique, 
indicating the existence of substantial genetic heterogene-
ity between primary and recurrent tumors. The majority of 
tumor pairs demonstrated complex clonal dynamics, with 
some of the subclonal mutations increasing and another 
decreasing in frequency between primary and relapse sam-
ples. Although all but four biopsies contained subclonal 
mutations, its frequency was relatively low suggesting a 
rather oligoclonal than policlonal nature of HGSOC. It 
should be emphasized here that the clonality analysis of 
a single tumor biopsy is restricted to the biopsy taken for 
analysis; therefore, it does not reflect the full spectrum of 
tumor subclonality (sampling-bias) [51]. Moreover, cur-
rently used sequencing strategies have a limited ability [52] 
to detect low prevalent subclones, hence a real subclonal 
complexity of HGSOC may be underestimated. Therefore, 
further studies should use more precise sequencing strate-
gies, such as a single cell sequencing, able to identify low 
prevalent subclones and, consequently, providing a full 
insight into the spatial subclonal composition of HGSOC 
and its evolution over time [53].
Branched CE in the progression of HGSOC from pri-
mary to reccurent disease has also been indicated by a 
case study using WES and comparative genome hybridisa-
tion to compare samples taken during debulking surgery 
first at initial diagnosis and second at disease relapse after 
treatment with platinum-based chemotherapy in combina-
tion with bevacizumab [54]. Only 42 out of 102 somatic 
mutations were common to all samples collected whereas 
21/102, 10/102 and 7/102 were unique to biopsies obtained 
from primary tumor, intra-pelvic and extra-pelvic recur-
rence, respectively. Even lower levels of concordance 
between the primary and the relapsed disease have been 
reported recently by two other studies using targeted re-
sequencing technology to compare mutational landscape 
in terms of 65 selected pharmacologically relevant genes 
between tumor samples taken before and after treatment 
with at least one line of chemotherapy [55, 56]. As one of 
these studies showed, the clonal architecture of recurrent 
tumors was more homogeneous than their primary counter-
parts suggesting that during ongoing evolution the majority 
of the somatic mutations were eliminated from cancer cell 
population by selective forces imposed by cancer therapy 
[56].
Studies provided consistent evidence that HGSOC con-
tinues evolution during the course of treatment follow-
ing highly individual patterns of CE [50, 54–56]. To date, 
however, little is known about how the differences in the 
evolutionary potentials of the tumors affect the clinical 
outcomes. In a recent paper, 135 samples from 14 patients 
with advanced-stage HGSOC, who received platinum-
based chemotherapy, were analyzed to evaluate the rela-
tionship between ITH and survival [27]. ITH was quantified 
as the degree of clonal expansion using the novel MEDICC 
(Minimum Event Distance for Intra-tumour Copy Number 
Comparisons) algorithm. As expected, the degree of clonal 
expansion differed considerably between patients, con-
firming earlier conclusions that HGSOC exhibits patient-
specific ITH [7, 25, 50]. Importantly, patients with higher 
clonal expansion had shorter progression-free and OS com-
pared to those with low clonal expansion, suggesting that 
highly heterogeneous polygenomic tumors have a greater 
predisposition to acquire treatment resistance, and, there-
fore, are characterized by poorer outcomes.
All studies that have monitored HGSOC evolution over 
the course of treatment consistently suggest that tumor 
relapse originates from drug-resistant subclone/s originally 
present in the primary tumor that expand under selective 
pressure of therapeutic intervention [27, 50, 54–56]. In 
contrast to some other cytotoxic drugs, such as temozolo-
mide [57], there are no evidences that the mutagenic activ-
ity of platinum could result in the generation of resistance 
de novo [12, 27, 50], implying that the role of platinum-
based chemotherapy in the arising of treatment resistance 
in HGSOC is limited to the selection of already present 
resistant subclones.
The fact that in all cases adjuvant chemotherapy failed 
to destroy resistant subclones [27, 50, 54–56] highlights 
that the primary cytoreductive surgery carried out pre-
cisely is essential in the management of HGSOC. From 
the HGSOC heterogeneity point of view, malignant lesions 
should be removed to the greatest extent possible to achieve 
long-term clinical benefits from the applied therapy. Other-
wise, minor resistant subclonal populations preoperatively 
widely distributed in tumor space may persist in the RD 
contributing to the rapid development of chemoresistance. 
It is clearly reflected by clinical observations indicating 
that the amount of RD left after primary surgery is a major 
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prognostic factor for survival in patients with EOC and the 
probability of emergence of resistance increases and the 
time to resistance decreases with the volume of RD [58, 
59]. Since RD should be regarded as a reservoir of resist-
ant subclones, the current efforts to reduce its amount by 
allowing resection of additional malignant tissue that nor-
mally remains invisible during surgery represent a very 
promising way to optimize therapy [60].
Conclusions and future directions
Advances in sequencing techniques have allowed us to look 
into the evolutionary nature of HGSOC, which in the light 
of current evidences can explain the relapsing course of 
the disease observed in clinical practice. Since only mini-
mal improvement in the survival of patients treated with 
standard therapy has been observed in the last decade, 
novel molecular targeted therapies are of great interest in 
HGSOC [61]. However, both spatial and temporal ITH 
pose a major challenge for personalized medicine [62], and 
greater knowledge of the molecular rules that drive tumor 
evolution through space and time is required to achieve a 
long-term clinical benefit from personalized therapy.
Since growing amount of evidence suggests that 
HGSOC relapse arises from outgrowth of pre-existing 
drug-resistant subclonal populations, further integrative 
genomic and phenotypic analyses using precise sequencing 
techniques should be carried out to define the molecular 
and genotypic signatures of resistant subclones. These data, 
respectively cataloged, could be used to evaluate the differ-
ences in the resistance patterns between individual patients 
and also could serve as a starting point for the design of 
novel therapeutic strategies. Further pre-clinical studies 
should give answer to a number of intriguing questions: 
(1) when do resistant subclones arise during the HGSOC 
evolution? (2) Whether they are distributed randomly or 
stochastically within the primary tumor? (3) What types of 
functional relationships do link them with dominant clones 
and surrounding non-malignant cells? (4) What is the role 
of microenvironmental niches in their selection or storage? 
(5) Whether their genotypes or phenotypes have a decisive 
influence on their positive selection? (6) Whether they are 
able to lead to recurrence autonomously or need support 
from the surrounding cells?
Personalized medicine requires tools to provide precise 
data on the subclonal composition of a patient’s tumor at 
the time of diagnosis, and which will also allow for regular 
tracking of its changes in relation to the therapeutic inter-
vention [63]. With the knowledge of how the subclonal 
composition of tumor changes under therapy, we will be 
able to set the combined or sequential treatment that can 
prevent selection of resistant subclones [64]. Therefore, 
more emphasis should be placed on the improvement of 
non-invasive approaches like the circulating plasma cell-
free DNA sequencing whose usefulness in determining 
HGSOC subclonality has been recently demonstrated [65, 
66].
Although existing evidences suggest that HGSOC dis-
plays highly individual patterns of CE, they are based on 
a relatively small number of cases. Therefore, further 
genomic analyses on representative groups of cases at dif-
ferent clinical stages should assess to what extent patterns 
of evolution are reproducible between patients and to what 
extent they are predictable in individual patients.
Heterogeneity is a hallmark of HGSOC. It must, there-
fore, be taken into account during efforts to improve effi-
ciency of standard therapy, as well as during design of 
novel personalized therapeutic strategies.
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